Share Price and Basic Stock Data
Last Updated: November 15, 2025, 11:17 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Genesis IBRC India Ltd operates in the seeds, tissue culture, and biotechnology sector, with its share price currently standing at ₹155 and a market capitalization of ₹201 Cr. The company has faced significant challenges in generating revenue, as evidenced by its sales figures, which have remained at ₹0.00 for multiple quarters from June 2022 through March 2024, with only a reported sales figure of ₹3.67 Cr for September 2024. Such a trend raises concerns about the company’s operational viability and market demand for its offerings. The absence of revenue generation over the past two years signals a critical need for strategic initiatives to revitalize its operations. The company’s historical sales peaked at ₹0.39 Cr in March 2014, but subsequently declined, demonstrating a troubling trend that needs immediate attention to reverse. The slow pace of recovery in sales could be detrimental to its long-term sustainability and growth prospects in a competitive industry landscape.
Profitability and Efficiency Metrics
Genesis IBRC India Ltd reported a net profit of ₹3.48 Cr, which translates to a high return on equity (ROE) and return on capital employed (ROCE) of 51.6%. However, the company has shown a concerning pattern in profitability metrics, particularly with negative operating profits recorded in previous quarters, culminating in an operating profit margin (OPM) of 94.82% for the trailing twelve months. This figure indicates a significant recovery in Q2 of FY 2025, where an operating profit of ₹3.65 Cr was recorded. Despite the high ROE, the company’s financial health appears precarious, given the historical losses and the current negative reserves of ₹4.47 Cr. The interest coverage ratio stands robust at 6.83x, suggesting the company can cover its interest obligations comfortably, yet the lack of consistent revenue generation remains a critical weakness that could undermine profitability moving forward.
Balance Sheet Strength and Financial Ratios
Genesis IBRC India Ltd maintains a balance sheet with no borrowings, a noteworthy achievement that provides financial flexibility. The company’s equity capital has remained steady at ₹13 Cr since March 2022, while its reserves have shown a negative trend, declining to ₹4.47 Cr by March 2025. This erosion of reserves poses potential liquidity risks in the long term. The price-to-book value ratio of 0.71x indicates that the stock is undervalued compared to its book value, which could attract value investors. However, the company’s cash conversion cycle remains unreported, leaving a gap in understanding its operational efficiency. The total liabilities stood at ₹8.83 Cr in March 2025, reflecting a manageable financial structure. The absence of long-term debt positions the company favorably, but the negative reserves highlight the need for improved operational performance to bolster financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genesis IBRC India Ltd reveals that promoters hold 11.33% of the total shares, while the public holds a substantial 88.68%. This distribution indicates a strong public interest in the company, with 1,736 shareholders recorded as of September 2025. The stability in promoter holdings suggests that there is confidence in the company’s long-term potential despite its recent operational challenges. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could reflect a cautious sentiment among larger investors, potentially due to the company’s inconsistent revenue generation and negative reserves. This lack of institutional backing may limit the company’s access to capital for future growth initiatives. Maintaining investor confidence will be critical as the company seeks to implement strategies for revenue recovery and sustainable growth.
Outlook, Risks, and Final Insight
Looking ahead, Genesis IBRC India Ltd faces both opportunities and challenges. The potential for recovery in sales, illustrated by the reported ₹3.67 Cr in September 2024, could signal a turnaround, yet the company must address its operational inefficiencies to sustain this growth. Risks include continued negative reserves and the historical trend of revenue stagnation, which could deter investor interest and affect capital raising efforts. Another concern is the reliance on a single quarter’s performance to gauge recovery, which may not be sustainable. To enhance its market position, the company must focus on innovation, strategic partnerships, and effective marketing to leverage its biotechnology capabilities. If successful, Genesis IBRC could transform its operational landscape, but failure to achieve consistent revenue may lead to further financial strain and diminished investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genesis IBRC India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 9.03 Cr. | 29.6 | 108/27.2 | 90.3 | 12.8 | 0.00 % | 11.8 % | 9.68 % | 10.0 |
| Genesis IBRC India Ltd | 226 Cr. | 174 | 185/16.6 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 131 Cr. | 14.3 | 22.8/10.7 | 9.67 | 4.78 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 318 Cr. | 167 | 239/138 | 6.74 | 362 | 1.20 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 23.5 Cr. | 21.4 | 43.0/19.7 | 30.5 | 27.0 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 225.00 Cr | 81.26 | 34.30 | 82.60 | 0.24% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.05 | 0.01 | 0.02 | 0.05 | 0.06 | 0.02 | 0.02 | 3.69 | 0.10 | 0.02 | 0.03 | 0.02 | 0.12 |
| Operating Profit | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| OPM % | 99.46% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| EPS in Rs | -0.04 | -0.01 | -0.02 | -0.04 | -0.05 | -0.02 | -0.02 | -2.84 | -0.08 | 2.81 | -0.02 | -0.02 | -0.09 |
Last Updated: August 19, 2025, 2:45 pm
Below is a detailed analysis of the quarterly data for Genesis IBRC India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.10 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.09. The value appears to be declining and may need further review. It has decreased from -0.02 (Mar 2025) to -0.09, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.39 | 0.78 | 0.00 | 0.00 | 0.29 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.55 | 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.23 |
| Operating Profit | -0.16 | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | -0.23 |
| OPM % | -41.03% | -19.23% | -68.97% | -100.00% | 95.37% | ||||||||
| Other Income | 0.01 | -0.09 | 0.42 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.18 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.33 | -0.45 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.33 | -0.44 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 |
| EPS in Rs | -1.09 | -0.62 | 0.36 | 0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.33% | 179.55% | -100.00% | 75.00% | -100.00% | -20.00% | 0.00% | -16.67% | -2614.29% | 192.11% |
| Change in YoY Net Profit Growth (%) | 0.00% | 212.88% | -279.55% | 175.00% | -175.00% | 80.00% | 20.00% | -16.67% | -2597.62% | 2806.39% |
Genesis IBRC India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 106% |
| 3 Years: | 215% |
| TTM: | 191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 40% |
| 3 Years: | 54% |
| 1 Year: | 152% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -2% |
| Last Year: | 52% |
Last Updated: September 5, 2025, 3:36 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28.08 | 229.29 | 62.93 | 292.00 | ||||||||
| Inventory Days | 104.29 | 0.00 | 0.00 | |||||||||
| Days Payable | 156.43 | |||||||||||
| Cash Conversion Cycle | -24.07 | 229.29 | 62.93 | 292.00 | ||||||||
| Working Capital Days | -1,272.82 | 1,586.35 | 5,991.03 | 67,890.00 | ||||||||
| ROCE % | -60.55% | -16.62% | 6.88% | 0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -0.03 |
| Diluted EPS (Rs.) | -0.03 |
| Cash EPS (Rs.) | 0.04 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 7.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 7.39 |
| Revenue From Operations / Share (Rs.) | 3.33 |
| PBDIT / Share (Rs.) | 0.14 |
| PBIT / Share (Rs.) | 0.06 |
| PBT / Share (Rs.) | 0.04 |
| Net Profit / Share (Rs.) | -0.02 |
| NP After MI And SOA / Share (Rs.) | -0.02 |
| PBDIT Margin (%) | 4.20 |
| PBIT Margin (%) | 2.02 |
| PBT Margin (%) | 1.41 |
| Net Profit Margin (%) | -0.78 |
| NP After MI And SOA Margin (%) | -0.78 |
| Return on Networth / Equity (%) | -0.35 |
| Return on Capital Employeed (%) | 0.87 |
| Return On Assets (%) | -0.27 |
| Current Ratio (X) | 3.24 |
| Quick Ratio (X) | 3.00 |
| Interest Coverage Ratio (X) | 6.83 |
| Interest Coverage Ratio (Post Tax) (X) | -0.27 |
| Enterprise Value (Cr.) | 6.58 |
| EV / Net Operating Revenue (X) | 1.52 |
| EV / EBITDA (X) | 36.12 |
| MarketCap / Net Operating Revenue (X) | 1.59 |
| Price / BV (X) | 0.71 |
| Price / Net Operating Revenue (X) | 1.59 |
After reviewing the key financial ratios for Genesis IBRC India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 18, the value is 0.04. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 18, the value is 3.33. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 18, the value is 0.14. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 18, the value is 0.06. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 18, the value is 0.04. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 18, the value is 4.20. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 18, the value is 2.02. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 18, the value is 1.41. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 18, the value is -0.35. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 18, the value is 0.87. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 18, the value is 3.24. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 18, the value is 3.00. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 6.83. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 18, the value is 6.58. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 18, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 18, the value is 36.12. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 18, the value is 0.71. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesis IBRC India Ltd:
- Net Profit Margin: -0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.87% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.35% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 34.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.78%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | Flat No.401, VVN Residency, 40-A, Ashok Nagar, Eluru Andhra Pradesh 534002 | csgenesisiil@gmail.com www.genesisiil.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Balakrishna Koppula | Whole Time Director |
| Mrs. Vanitha Nagulavari | Non Executive Director |
| Mr. Prasada Rao Kalluri | Independent Director |
| Mr. Mohammed Baba | Independent Director |